Watch ELAN. Know when insiders buy.
One email the day a filing lands. Free.
Work order
90
PASS · insiders 79, shorts 100
Insiders, 90 days
+$936K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $12.2BP/E —DIV YIELD —FCF YIELD 3.10%REV TTM $5B +12.0%NET INCOME −$199M −145.9%NET DEBT $3.1B52W 18.33 – 26.84NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.4B | +10.2% | 58.3% | — | $54M | +390.9% | 0.11 | $277M | $33M | $244M | Aug 5 |
| Q1 2026 · Mar 31 | $1.4B | +14.9% | 57.3% | — | $57M | −14.9% | 0.11 | $13M | $51M | −$38M | Aug 5 |
| Q4 2025 · Dec 31derived | $1.1B | +12.2% | 51.5% | — | −$276M | — | -0.56 | $108M | $62M | $46M | Feb 24 |
| Q3 2025 · Sep 30 | $1.1B | +10.4% | 53.4% | — | −$34M | −109.3% | -0.07 | $219M | $92M | $127M | Nov 5 |
| Q2 2025 · Jun 30 | $1.2B | +4.8% | 57.5% | — | $11M | — | 0.02 | $237M | $57M | $180M | Aug 5 |
| Q1 2025 · Mar 31 | $1.2B | −1.0% | 57.3% | — | $67M | +109.4% | 0.13 | −$4M | $65M | −$69M | Aug 5 |
| Q4 2024 · Dec 31derived | $1B | −1.4% | 50.9% | — | −$8M | — | -0.02 | $177M | $47M | $130M | Feb 24 |
| Q3 2024 · Sep 30 | $1B | −3.6% | 52.2% | — | $364M | — | 0.73 | $162M | $42M | $120M | Nov 5 |
| Q2 2024 · Jun 30 | $1.2B | — | 58.2% | — | −$50M | — | -0.10 | $200M | $34M | $166M | Nov 5 |
| Q1 2024 · Mar 31 | $1.2B | — | 57.3% | — | $32M | — | 0.06 | $2M | $24M | −$22M | Nov 5 |
| Q4 2023 · Dec 31derived | $1B | — | 50.1% | — | −$141M | — | -0.29 | $157M | $41M | $116M | Feb 24 |
| Q3 2023 · Sep 30 | $1.1B | — | 54.4% | — | −$1.1B | — | -2.22 | $198M | $33M | $165M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $4.7B | 55.0% | — | −$232M | -4.9% | -0.47 | $560M | $276M | $284M | — | — |
| FY2024 · to Dec 31 | $4.4B | 54.9% | — | $338M | 7.6% | 0.68 | $541M | $147M | $394M | — | — |
| FY2023 · to Dec 31 | $4.4B | 56.3% | — | −$1.2B | -27.9% | -2.50 | $271M | $140M | $131M | — | — |
| FY2022 · to Dec 31 | $4.4B | 56.6% | — | −$78M | -1.8% | -0.16 | $452M | $171M | $281M | — | — |
| FY2021 · to Dec 31 | $4.8B | 55.2% | — | −$483M | -10.1% | -0.99 | $483M | $159M | $324M | — | — |
| FY2020 · to Dec 31 | $3.3B | 49.1% | — | −$574M | -17.5% | -1.30 | −$41M | $135M | −$176M | — | — |
Every number comes from Elanco Animal Health Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.